콘드로이틴 황산 시장 기회, 성장 촉진요인, 업계 동향 분석 및 예측(2026-2035년)

The Global Chondroitin Sulphate Market was valued at USD 1.5 billion in 2025 and is estimated to grow at a CAGR of 5.3% to reach USD 2.4 billion by 2035.

The increasing prevalence of osteoarthritis provides a strong and sustained demand base for chondroitin sulphate, particularly as joint-health concerns continue to affect a large global population. The World Health Organization recognizes osteoarthritis as a significant contributor to disability worldwide and estimates that more than 500 million people are living with the condition. Chondroitin sulphate continues to attract demand because of its established use in joint-health products and pharmaceutical applications. Manufacturers are increasingly emphasizing raw-material quality, regulatory compliance, standardized processing, and supply consistency to meet requirements across pharmaceutical, nutraceutical, and other end-use markets. Demand is also being supported by growing consumer awareness of joint-health products and expanding supplement distribution channels. At the same time, producers are differentiating their offerings through source-specific products and higher-quality grades. These factors are helping sustain market growth while encouraging suppliers to strengthen production capabilities and maintain reliable access to qualified chondroitin sulphate ingredients.

Bovine chondroitin sulphate segment generated USD 589 million in 2025. Its strong position is supported by established pharmacopoeial recognition, reliable access to cattle-derived cartilage, and its long-standing presence in pharmaceutical-grade manufacturing. Sioux Pharm's Chondropure(TM) and Bioiberica's CSbioactive(R) reflect the premium market's focus on traceable bovine sourcing and strong regulatory documentation. Revenue from bovine chondroitin sulphate is expected to reach approximately USD 900 million by 2035, corresponding to a 4.5% CAGR. Despite this increase in revenue, its market share is projected to moderate to 37.5% by 2035 as other sources gain greater participation.

Powder segment captured USD 839 million in 2025. Bulk powder serves as a key input for contract manufacturing, pharmaceutical compounding, dietary supplement production, and cosmetic formulation. Its flexibility allows manufacturers to use a qualified powder ingredient across multiple downstream formats, including capsules, tablets, liquid formulations, and topical products. Synutra's Chondro Gold(TM) and Yantai Dongcheng's sodium chondroitin sulphate API demonstrate the role of standardized powder specifications in connecting primary extraction with finished-product manufacturing. Powder is expected to maintain its leading position through 2035, reaching approximately USD 1.37 billion at a 5% CAGR.

North America Chondroitin Sulphate Market recorded a 38.2% share in 2025. The United States contributed USD 464.4 million and is forecast to reach USD 755.1 million by 2035, advancing at a 5% CAGR. Canada generated USD 108.6 million and is expected to grow at a 3.2% CAGR. Strong consumer familiarity with dietary supplements, well-developed online retail channels, and demand for joint-health solutions influenced through healthcare professionals continue to support regional market expansion. The established supplement ecosystem in North America also provides manufacturers with multiple routes to reach consumers and maintain demand for chondroitin sulphate-based products.

Major companies operating in the global chondroitin sulphate market include Seikagaku Corporation, Merck KGaA, Shandong Runxin Biotechnology, Synutra Ingredients, and Yantai Dongcheng Pharmaceutical Group. Companies in the global chondroitin sulphate market are strengthening their competitive positions through source diversification, quality enhancement, regulatory compliance, product development, and supply-chain expansion. Leading participants are focusing on standardized raw materials and controlled manufacturing processes to deliver consistent product quality across pharmaceutical and supplement applications. Companies are also investing in traceability systems and documentation to meet increasingly stringent customer and regulatory requirements. Expanding product portfolios across different grades and forms allows manufacturers to serve a wider range of formulation needs. Strategic partnerships with pharmaceutical, nutraceutical, and ingredient companies help suppliers strengthen distribution networks and secure long-term commercial relationships. Producers are also increasing their focus on efficient sourcing and reliable production capacity to reduce supply disruptions. Geographic expansion and stronger digital distribution channels provide additional opportunities to reach emerging customers. By combining quality assurance, innovation, regulatory capabilities, and broader market access, industry participants are working to reinforce their presence and capture a larger share of the growing chondroitin sulphate market.

Table of Contents

Chapter 1. Methodology & Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Data mining sources
  • 1.3.1 Global
  • 1.3.2 Regional/Country
• 1.4 Base estimates and calculations
  • 1.4.1 Base year calculation
  • 1.4.2 Key trends for market estimation
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
• 1.6 Forecast model
• 1.7 Research assumptions and limitations

Chapter 2. Executive Summary

• 2.1 Industry 360° synopsis
• 2.2 Key market trends
  • 2.2.1 Regional
  • 2.2.2 Source
  • 2.2.3 Form
  • 2.2.4 Application
  • 2.2.5 Distribution Channel
• 2.3 TAM Analysis, 2025-2034
• 2.4 CXO perspectives: Strategic imperatives
  • 2.4.1 Executive decision points
  • 2.4.2 Critical success factors
• 2.5 Future Outlook and Strategic Recommendations

Chapter 3. Industry Insights

• 3.1 Industry ecosystem analysis
  • 3.1.1 Supplier landscape
  • 3.1.2 Profit margin
  • 3.1.3 Value addition at each stage
  • 3.1.4 Factor affecting the value chain
  • 3.1.5 Disruptions
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
  • 3.2.2 Industry pitfalls and challenges
  • 3.2.3 Market opportunities
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
  • 3.4.4 Latin America
  • 3.4.5 Middle East & Africa
• 3.5 Porter’s analysis
• 3.6 PESTEL analysis
• 3.7 Price trends
• 3.8 Future market trends
• 3.9 Technology and Innovation landscape
  • 3.9.1 Current technological trends
  • 3.9.2 Emerging technologies
• 3.10 Patent Landscape
• 3.11 Trade statistics (HS code) (Note: the trade statistics will be provided for key countries only)
  • 3.11.1 Major importing countries
  • 3.11.2 Major exporting countries

Chapter 4. Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
  • 4.2.1 By region
    • 4.2.1.1 North America
    • 4.2.1.2 Europe
    • 4.2.1.3 Asia Pacific
    • 4.2.1.4 LATAM
    • 4.2.1.5 MEA
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Mergers & acquisitions
  • 4.6.2 Partnerships & collaborations
  • 4.6.3 New Product Launches
  • 4.6.4 Expansion Plans

Chapter 5. Market Estimates and Forecast, By Source, 2022-2035 (USD Million & Tons)

• 5.1 Key trends
• 5.2 Bovine
• 5.3 Porcine
• 5.4 Avian
  • 5.4.1 Chicken
  • 5.4.2 Turkey
  • 5.4.3 Others
• 5.5 Marine
  • 5.5.1 Tuna
  • 5.5.2 Salmon
  • 5.5.3 Others
• 5.6 Others

Chapter 6. Market Estimates and Forecast, By Form, 2022-2035 (USD Million & Tons)

• 6.1 Key trends
• 6.2 Powder
• 6.3 Capsule/Tablets
• 6.4 Liquid

Chapter 7. Market Estimates and Forecast, By Application, 2022-2035 (USD Million & Tons)

• 7.1 Key trends
• 7.2 Dietary Supplements
  • 7.2.1 Capsules
  • 7.2.2 Tablets
  • 7.2.3 Gummies
• 7.3 Pharmaceuticals
  • 7.3.1 Osteoarthritis treatment drugs
  • 7.3.2 Joint health formulations
• 7.4 Cosmetic and Personal Care
  • 7.4.1 Anti-aging creams
  • 7.4.2 Skin hydration products
• 7.5 Food and Beverages
• 7.6 Others

Chapter 8. Market Estimates and Forecast, By Distribution Channel, 2022-2035 (USD Million & Tons)

• 8.1 Key trends
• 8.2 Direct Sales
• 8.3 Distributors
• 8.4 Online Retail
• 8.5 Pharmacies

Chapter 9. Market Estimates and Forecast, By Region, 2022-2035 (USD Million & Tons)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 India
  • 9.4.3 Japan
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 Saudi Arabia
  • 9.6.2 South Africa
  • 9.6.3 UAE
  • 9.6.4 Rest of Middle East and Africa

Chapter 10. Company Profiles

• 10.1 TSI Group Ltd.
• 10.2 Synutra Ingredients (Shandong) Co., Ltd.
• 10.3 Yantai Dongcheng Pharmaceutical Group Co., Ltd.
• 10.4 Jiaxing Hengjie Biopharmaceutical Co., Ltd.
• 10.5 Qufu Liyang Biochem Industrial Co., Ltd.
• 10.6 Pacific Rainbow International, Inc.
• 10.7 Shandong Runxin Biotechnology Co., Ltd.
• 10.8 ZPD A/S
• 10.9 Guangdong Hybribio Biotech Co., Ltd.
• 10.10 Wanbury Limited
• 10.11 Sierra Ingredients Pty Ltd.
• 10.12 BGM Pharmaceuticals Co., Ltd.
• 10.13 YBCC (Qingdao) Co., Ltd.
• 10.14 Anhui Jintung Fine Chemical Corporation Ltd.